These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 1501073)

  • 1. Crystal structures of a new oral iron chelator, 1,2-dimethyl-3-hydroxy-4-pyridone, and its solvates with acetic acid and formic acid.
    Chan HK; Ghosh S; Venkataram S; Rahman YE; Grant DJ
    J Pharm Sci; 1992 Apr; 81(4):353-8. PubMed ID: 1501073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationships between crystal structures, thermal properties, and solvate stability of dialkylhydroxypyridones and their formic acid solvates.
    Ghosh S; Ojala WH; Gleason WB; Grant DJ
    J Pharm Sci; 1995 Dec; 84(12):1392-9. PubMed ID: 8748319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hydrogen-bond patterns of dialkylpyridone iron chelators and their 1:1 formic acid solvates: description, prediction, and role in crystal packing.
    Ghosh S; Adsmond DA; Huotari J; Grant DJ
    J Pharm Sci; 1993 Sep; 82(9):901-11. PubMed ID: 8229688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationships between solution thermodynamics and hydrogen-bond patterns of crystalline dialkylhydroxypyridone iron chelators and their formic acid solvates.
    Ghosh S; Adsmond DA; Grant DJ
    J Pharm Sci; 1995 May; 84(5):568-74. PubMed ID: 7658346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Solid state properties of an oral iron chelator, 1,2-dimethyl-3-hydroxy-4-pyridone, and its acetic acid solvate. I: Physicochemical characterization, intrinsic dissolution rate, and solution thermodynamics.
    Chan HK; Venkataram S; Grant DJ; Rahman YE
    J Pharm Sci; 1991 Jul; 80(7):677-85. PubMed ID: 1941568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Studies on an oral iron chelator: 1,2-dimethyl-3-hydroxy-pyrid-4-one (DMHP). Mechanism of intestinal absorption in rabbits.
    Railkar AM; Awni WM; Camp RJ; Rahman YE
    J Pharm Pharmacol; 1993 May; 45(5):400-5. PubMed ID: 8099956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure of 6-(3,3-dimethyl-2-oxo-2,3-dihydro-5-furanyl)-2-pyridone at 145 K.
    Maverick E; Chiefari J; Lightner DA
    Acta Crystallogr C; 1993 Feb; 49 ( Pt 2)():338-40. PubMed ID: 8452682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmaceutical analysis of the oral iron chelator deferiprone (DMHP,L1).
    Lange R; Lameijer W; Slijkhuis C; de Kaste D
    Pharm World Sci; 1996 Aug; 18(4):142-7. PubMed ID: 8873230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis, characterization, and structures of Mn(DMHP)3 x 12H2O and Mn(DMHP)2Cl x 0.5H2O.
    Hsieh WY; Liu S
    Inorg Chem; 2005 Mar; 44(6):2031-8. PubMed ID: 15762730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The kinetics of dimethylhydroxypyridinone interactions with iron(iii) and the catalysis of iron(iii) ligand exchange reactions: implications for bacterial iron transport and combination chelation therapies.
    Harrington JM; Mysore MM; Crumbliss AL
    Dalton Trans; 2018 May; 47(20):6954-6964. PubMed ID: 29721567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pseudoacids. I. 4- and 5-oxoacids.
    Valente EJ; Fuller JF; Ball JD
    Acta Crystallogr B; 1998 Apr; 54 ( Pt 2)():162-73. PubMed ID: 9581270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two novel polymorphic forms of iron-chelating agent deferiprone.
    Rajendrakumar S; Durga ASVS; Nanubolu JB; Balasubramanian S
    Acta Crystallogr C Struct Chem; 2020 Feb; 76(Pt 2):193-200. PubMed ID: 32022715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The series of molecular conductors and superconductors ET4[AFe(C2O4)3]·PhX (ET = bis(ethylenedithio)tetrathiafulvalene; (C2O4)2- = oxalate; A+ = H3O+, K+; X = F, Cl, Br, and I): influence of the halobenzene guest molecules on the crystal structure and superconducting properties.
    Coronado E; Curreli S; Giménez-Saiz C; Gómez-García CJ
    Inorg Chem; 2012 Jan; 51(2):1111-26. PubMed ID: 22220827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crystal form III of beta-cyclodextrin-ethanol inclusion complex: layer-type structure with dimeric motif.
    Aree T; Chaichit N
    Carbohydr Res; 2008 Sep; 343(13):2285-91. PubMed ID: 18490008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microencapsulation of an iron chelator for sustained release and crystal habit modification.
    Venkataram S; Khohlokwane M
    J Microencapsul; 1996; 13(5):519-25. PubMed ID: 8864989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structures of 2,6-disubstituted naphthalenes.
    Kaduk JA; Golab JT
    Acta Crystallogr B; 1999 Feb; 55(Pt 1):85-94. PubMed ID: 10927342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 2-hydroxypyridine <--> 2-pyridone tautomerization: catalytic influence of formic acid.
    Hazra MK; Chakraborty T
    J Phys Chem A; 2006 Jul; 110(29):9130-6. PubMed ID: 16854025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic comparison of the mono-, dimethyl- and trimethyl 3-hydroxy-4(1H)-pyridones - Attempted optimization of the orally active iron chelator, deferiprone.
    Xie YY; Lu Z; Kong XL; Zhou T; Bansal S; Hider R
    Eur J Med Chem; 2016 Jun; 115():132-40. PubMed ID: 27014847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Channel-forming solvates of 6-chloro-2,5-dihydroxypyridine and its solvent-free tautomer 6-chloro-5-hydroxy-2-pyridone.
    Parkin SR; Behrman EJ
    Acta Crystallogr C; 2009 Oct; 65(Pt 10):o529-33. PubMed ID: 19805888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Solvates of zafirlukast.
    Goldring D; Botoshansky M; Khalfin RL; Pertsikov B; Nisnevitch G; Ponomarev V; Zaltzman I; Gutman A; Kaftory M
    Acta Crystallogr C; 2004 Dec; 60(Pt 12):o843-6. PubMed ID: 15579961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.